Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TRVI | US
0.23
7.37%
Healthcare
Biotechnology
30/06/2024
21/10/2024
3.35
3.16
3.44
3.16
Trevi Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio an oral extended-release formulation of nalbuphine which is in phase 2b/3 clinical trial for the treatment of chronic pruritus chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven Connecticut.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
71.7%1 month
70.7%3 months
68.4%6 months
69.1%-
-
3.42
0.02
0.02
-4.92
-
-
-43.03M
243.18M
243.18M
-
-
-
-
-48.09
3.46
3.34
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.61
Range1M
0.73
Range3M
1.19
Rel. volume
3.58
Price X volume
5.32M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ChromaDex Corporation | CDXC | Biotechnology | 3.46 | 262.73M | -1.14% | n/a | 10.17% |
| Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 14.81 | 260.58M | -1.99% | n/a | -201.68% |
| Mersana Therapeutics Inc | MRSN | Biotechnology | 2.1 | 257.62M | 0.00% | n/a | 383.37% |
| 2seventy bio Inc | TSVT | Biotechnology | 4.97 | 255.94M | -0.40% | n/a | 107.07% |
| Nektar Therapeutics | NKTR | Biotechnology | 1.39 | 255.87M | -1.42% | n/a | 275.58% |
| Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.85 | 254.54M | -0.54% | n/a | 0.00% |
| Acrivon Therapeutics Inc. | ACRV | Biotechnology | 8.05 | 249.33M | -2.42% | n/a | 1.95% |
| Poseida Therapeutics Inc | PSTX | Biotechnology | 2.5 | 242.83M | 2.04% | n/a | 137.55% |
| MacroGenics Inc | MGNX | Biotechnology | 3.86 | 242.11M | -3.74% | n/a | 58.90% |
| Omeros Corporation | OMER | Biotechnology | 4.1 | 237.58M | -1.20% | n/a | -356.63% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CPI Card Group Inc | PMTS | Building Products & Equipment | 23.4 | 261.09M | -1.39% | 15.61 | -621.78% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.53 | 236.68M | -1.96% | 9.09 | 39.79% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.55 | 145.88M | -0.79% | n/a | 58.43% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.87 | 94.40M | 1.83% | 5.16 | 19.82% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 14.22 | 89.04M | -1.80% | 14.48 | 7.10% |
| Urban One Inc | UONEK | Broadcasting - Radio | 1.01 | 53.54M | -3.35% | n/a | 268.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.92 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.42 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 68.37 | - | Par |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 243.18M | - | Emerging |